Convalescent plasma for people with COVID-19: a living systematic review

Author:

Iannizzi Claire1,Chai Khai Li2,Piechotta Vanessa3,Valk Sarah J45,Kimber Catherine6,Monsef Ina3,Wood Erica M2,Lamikanra Abigail A7,Roberts David J6,McQuilten Zoe2,So-Osman Cynthia89,Jindal Aikaj10,Cryns Nora1,Estcourt Lise J11,Kreuzberger Nina3,Skoetz Nicole3

Affiliation:

1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne; University of Cologne; Cologne Germany

2. Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia

3. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

4. Jon J van Rood Center for Clinical Transfusion Research; Sanquin/Leiden University Medical Center; Leiden Netherlands

5. Department of Clinical Epidemiology; Leiden University Medical Center; Leiden Netherlands

6. Systematic Review Initiative; NHS Blood and Transplant; Oxford UK

7. Clinical, Research and Development; NHS Blood and Transplant; Oxford UK

8. Sanquin Blood Bank; Amsterdam Netherlands

9. Erasmus Medical Centre; Rotterdam Netherlands

10. Department of Transfusion Medicine; SPS Hospitals; Ludhiana (Punjab) India

11. Haematology/Transfusion Medicine; NHS Blood and Transplant; Oxford UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference471 articles.

1. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial);Mukherjee;medRxiv [Preprint],2020

2. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial);Agarwal;BMJ,2020

3. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939);Agarwal;The BMJ,2020

4. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial;Alemany;Lancet Respiratory Medicine,2022

5. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease;AlQahtani;MedRxiv [Preprint],2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3